Meda AB
Swedish specialty pharmaceutical company acquired by Mylan in 2016.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Meda AB was a Swedish specialty pharmaceutical company headquartered in Solna. Its business focused on importing, developing, marketing, and distributing pharmaceuticals, nutritional products, and other health-care products across international markets. In addition to commercializing medicines, the company provided services connected with clinical research, regulatory registration, supply-chain logistics, and product distribution. Meda operated with an international portfolio rather than relying exclusively on internally discovered medicines. Its growth model combined the acquisition of pharmaceutical businesses and brands with the commercialization of products obtained from other companies. This approach allowed Meda to expand geographically, add therapeutic categories, and build a broad portfolio in prescription medicines, consumer health, nutrition, and related health-care segments. A major early expansion occurred in 2005, when Meda acquired the German pharmaceutical company Viatris GmbH from Advent International for €750 million. The transaction strengthened Meda's European business and added an established pharmaceutical platform. In 2007, Meda announced and completed the acquisition of MedPointe, a New Jersey-based pharmaceutical company, in a cash-and-stock transaction reported at approximately $800 million. The deal gave Meda a stronger presence in the United States. MedPointe had previously acquired the diagnostics and drug businesses of Carter-Wallace, while Carter-Wallace's consumer products business had been sold separately to Church & Dwight. Meda continued to broaden its portfolio through acquisitions. In 2014, it acquired the Italian company Rottapharm Madaus, adding consumer-health products and expanding its presence in Italy and other markets. The company also examined a possible divestment of its United States division in 2015 as part of efforts to generate funds for expansion in other areas. This reflected the portfolio-management strategy common to specialty pharmaceutical companies, in which businesses and product groups are periodically reassessed for strategic fit and capital requirements. By the end of 2014, Meda had 5,202 employees, and its products were sold in more than 150 countries. The company remained a publicly traded Swedish pharmaceutical business until 2016, when Mylan acquired it through a cash-and-stock offer valued at approximately €7.2 billion. The transaction ended Meda's independent existence as a listed company and brought its operations and product portfolio into Mylan. Accordingly, Meda AB is best understood as a former international specialty-pharmaceutical company whose principal legacy lies in its acquired and marketed product portfolio and its multinational commercial infrastructure.
History
Meda AB developed as an international specialty-pharmaceutical business based in Sweden. Rather than operating only as a research-based drug inventor, it built its business around the acquisition, registration, marketing, importation, and distribution of pharmaceutical and health-care products. Its operating model also included clinical-research support and logistics, enabling it to commercialize products across multiple jurisdictions. The company pursued an acquisition-led expansion strategy during the 2000s. In 2005, Meda bought the German pharmaceutical company Viatris GmbH from Advent International for €750 million. The transaction expanded Meda's European platform and gave it an established pharmaceutical business through which it could strengthen its regional portfolio. Meda next targeted the United States. On 20 July 2007, it announced an approximately $800 million cash-and-stock agreement to acquire MedPointe from a group of U.S. investors. The transaction was completed on 22 August 2007. MedPointe had acquired the diagnostics and drug businesses of Carter-Wallace in 2001; Carter-Wallace's consumer-product activities had gone separately to Church & Dwight. Following the deal, Meda entered the U.S. market more substantially, while the new investors received an aggregate stake of approximately 7% in Meda. The company continued to use acquisitions to diversify its product base and geographic reach. In 2014, Meda acquired the Italian firm Rottapharm Madaus. The transaction was particularly relevant to Meda's consumer-health ambitions because it added consumer products to the company's portfolio. In 2015, Meda examined whether to divest its U.S. division, Meda Pharmaceuticals, to raise funds for investment and expansion in other areas. The review illustrates the company's willingness to reshape its portfolio as market opportunities and capital requirements changed. At the end of 2014, Meda employed 5,202 people. Its products were sold in more than 150 countries, making it a substantial international commercial organization despite its Swedish headquarters. The company's activities covered pharmaceuticals as well as nutritional and broader health-care products, supported by services in clinical research, regulatory registration, and logistics. Meda's independent corporate history ended in 2016. Mylan acquired the company through a cash-and-stock offer valued at approximately €7.2 billion. Before the transaction, Meda had been listed on the Stockholm Stock Exchange. The acquisition removed Meda from independent stock-market trading and transferred its operations and portfolio into Mylan. Meda AB is therefore a defunct independent corporate brand, although products and capabilities associated with the business became part of the acquiring company's broader pharmaceutical platform.
- 2016
Acquisition by Mylan
[1]Mylan acquired Meda through a cash-and-stock offer valued at approximately €7.2 billion, ending Meda's independent listed-company status.
- 2015
Review of U.S. division
[1]Meda explored a possible divestment of its U.S. division to raise funds for expansion in other areas.
- 2014
Acquisition of Rottapharm Madaus
[1]Meda acquired the Italian company Rottapharm Madaus, adding consumer-health products to its portfolio.
- 2014
International commercial scale
[1]At year-end, Meda reported 5,202 employees and products sold in more than 150 countries.
- 2007
Agreement to acquire MedPointe
[1]Meda announced an approximately $800 million cash-and-stock transaction for New Jersey-based pharmaceutical company MedPointe.
- 2007
Completion of MedPointe acquisition
[1]The MedPointe acquisition closed on 22 August, giving Meda a stronger presence in the United States.
- 2005
Acquisition of Viatris GmbH
[1]Meda acquired the German pharmaceutical company Viatris GmbH from Advent International for €750 million, strengthening its European pharmaceutical platform.
Products and positioning
An acquisition-led, internationally oriented specialty-pharmaceutical company combining pharmaceutical commercialization with consumer health, nutrition, regulatory, clinical-research, and logistics capabilities.
Pharmaceuticals
Prescription pharmaceuticals
Meda's core portfolio consisted of prescription pharmaceutical products that it imported, registered, marketed, and distributed internationally. The company expanded this portfolio substantially through acquisitions, including Viatris GmbH and MedPointe. Specific product names are not identified in the supplied reference material.
Consumer health · 2014
Consumer-health products
Consumer health became a more important part of Meda's portfolio after its acquisition of Rottapharm Madaus in 2014. These products complemented the company's prescription-pharmaceutical activities and helped broaden its exposure to non-prescription and self-care markets.
Nutrition and health care
Nutritional and health-care products
Alongside medicines, Meda imported and marketed nutritional products and other health-care products. The supplied references describe these as part of the company's wider international commercial offering but do not identify individual brands or formulations.
Brand decisions
2016
Accept acquisition by MylanM&ABackground
Meda became the target of a large-scale pharmaceutical-industry acquisition.
Action taken
Mylan acquired Meda through a cash-and-stock offer valued at approximately €7.2 billion.
Aftermath
Meda ceased to operate as an independent listed company and became part of Mylan.
Acquisition offer value. Approximately €7.2 billion (2016)
2015
Consideration of U.S. division divestmentStrategyBackground
Meda reviewed ways to raise funds for expansion in areas outside its U.S. business.
Action taken
The company explored the possible sale of Meda Pharmaceuticals, its United States division.
Aftermath
The supplied reference material does not establish that a divestment was completed.
2014
Acquire Rottapharm MadausM&ABackground
Meda aimed to broaden its product portfolio beyond prescription pharmaceuticals and add consumer-health products.
Action taken
Meda acquired Italian company Rottapharm Madaus.
Aftermath
The deal expanded Meda's consumer-health offering and international portfolio.
2007
Acquire MedPointeM&ABackground
Meda pursued a substantial expansion into the United States and sought to add MedPointe's pharmaceutical and diagnostic activities to its portfolio.
Action taken
Meda announced and completed a cash-and-stock acquisition of MedPointe.
Aftermath
The acquisition gave Meda a stronger U.S. presence; the new investors held approximately 7% of Meda in aggregate.
Reported transaction value. Approximately $800 million (2007)
2005
Acquire Viatris GmbHM&ABackground
Meda sought to expand its European pharmaceutical business through the purchase of an established German pharmaceutical company.
Action taken
Meda acquired Viatris GmbH from Advent International for €750 million.
Aftermath
The transaction strengthened Meda's European operating and product platform.
Acquisition price. €750 million (2005)
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/meda-ab · Editorial policy · How profiles are compiled